- Home
- ARMK vs PCVX Comparison
ARMK vs PCVX Comparison
Compare ARMK & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMK
- PCVX
- Stock Information
- Founded
- ARMK 1959
- PCVX 2013
- Country
- ARMK United States
- PCVX United States
- Employees
- ARMK N/A
- PCVX N/A
- Industry
- ARMK Restaurants
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- ARMK Consumer Discretionary
- PCVX Health Care
- Exchange
- ARMK Nasdaq
- PCVX Nasdaq
- Market Cap
- ARMK 10.1B
- PCVX 4.0B
- IPO Year
- ARMK 2013
- PCVX 2020
- Fundamental
- Price
- ARMK $38.71
- PCVX $43.85
- Analyst Decision
- ARMK Strong Buy
- PCVX Strong Buy
- Analyst Count
- ARMK 9
- PCVX 8
- Target Price
- ARMK $45.67
- PCVX $114.17
- AVG Volume (30 Days)
- ARMK 2.2M
- PCVX 1.7M
- Earning Date
- ARMK 11-17-2025
- PCVX 11-05-2025
- Dividend Yield
- ARMK 1.07%
- PCVX N/A
- EPS Growth
- ARMK 3.13
- PCVX N/A
- EPS
- ARMK 1.36
- PCVX N/A
- Revenue
- ARMK $17,874,782,000.00
- PCVX N/A
- Revenue This Year
- ARMK $9.17
- PCVX N/A
- Revenue Next Year
- ARMK $5.82
- PCVX N/A
- P/E Ratio
- ARMK $28.79
- PCVX N/A
- Revenue Growth
- ARMK 4.02
- PCVX N/A
- 52 Week Low
- ARMK $29.92
- PCVX $27.66
- 52 Week High
- ARMK $44.49
- PCVX $116.00
- Technical
- Relative Strength Index (RSI)
- ARMK 45.21
- PCVX 62.86
- Support Level
- ARMK $39.50
- PCVX $41.24
- Resistance Level
- ARMK $40.26
- PCVX $45.50
- Average True Range (ATR)
- ARMK 0.77
- PCVX 1.59
- MACD
- ARMK -0.05
- PCVX -0.22
- Stochastic Oscillator
- ARMK 25.57
- PCVX 61.27
About ARMK Aramark
Aramark, founded in 1936 and headquartered in Philadelphia, Pennsylvania, operates as a food service company providing facility management and workplace solutions. The company primarily generates revenue from its North American food and support services segment, serving various clients including schools, healthcare facilities, and entertainment venues.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.